Regeneron sees strong initial demand for higher-dose Eylea
Reuters
Published Nov 02, 2023 06:48AM ET
Updated Nov 02, 2023 12:01PM ET
By Sriparna Roy
(Reuters) -Regeneron Pharmaceuticals on Thursday said it is seeing strong initial demand for its recently launched higher-dose version for eye drug Eylea.
The launch should potentially bring the treatment back to growth, according to analysts. Eylea has missed Wall Street sales expectations so far this year, partly due to competition from Roche's Vabysmo since the rival secured U.S. approval last year.
Regeneron (NASDAQ:REGN) in a post-earnings call said physicians are prescribing the higher-dose version in patients who are switching from rival drugs and those who are new to the medicine.
"In terms of the switches, it's early days. We are seeing switches from (regular dose) Eylea, as you would expect ... the early reports have been quite encouraging," said company executive Marion McCourt, adding there have been switches from other products as well.
Eylea's sales for the third quarter fell 11% to $1.49 billion, which included $43 million sales from the higher dose, or 8 milligram dose that was launched in the United States in August.
With the launch, this could be the last quarter where Vabysmo hits Eylea sales, said Wells Fargo analyst Mohit Bansal.
Bansal was expecting $40 million in sales for the higher dose of the drug in the current quarter and $133 million in 2023.
Regeneron shares rose 4.6% after the company beat Wall Street estimates for third-quarter profit.
The profit beat was driven by strong demand for its eczema treatment, Dupixent, which rose 33% to $3.10 billion, as recorded by its partner Sanofi (NASDAQ:SNY).
On an adjusted basis, Regeneron earned $11.59 per share for the quarter, above analysts' estimates of $10.72, according to LSEG data.
The company's total revenue of $3.36 billion beat expectations of $3.23 billion.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.